An update on the development of drugs for neuropsychiatric disorders: focusing on the σ₁ receptor ligand

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.12, Iss.1, 2008-01, pp. : 45-58

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

-1 Receptor Ligands: Potential in the Treatment of Neuropsychiatric Disorders

By Hayashi T. Su T-P.

CNS Drugs, Vol. 18, Iss. 5, 2004-01 ,pp. : 269-284

Adis International

Access to resources Recommend Favorite

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders

By Hayashi Teruo Tsai Shang-Yi Mori Tomohisa Fujimoto Michiko Su Tsung-Ping

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 5, 2011-05 ,pp. : 557-577

Informa Healthcare

Access to resources Recommend Favorite

Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases

Current Pharmaceutical Design, Vol. 18, Iss. 7, 2012-03 ,pp. : 875-883

Bentham Science Publishers

Access to resources Recommend Favorite

Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders

By Vinod K Yaragudri Hungund Basalingappa L

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 2, 2006-04 ,pp. : 203-210

Informa Healthcare

Access to resources Recommend Favorite

Nicotine and Nicotinic Receptor Involvement in Neuropsychiatric Disorders

Current Topics in Medicinal Chemistry, Vol. 4, Iss. 3, 2004-01 ,pp. : 267-282

Bentham Science Publishers

Access to resources Recommend Favorite